This site is intended for healthcare professionals
  • Home
  • /
  • Event
  • /
  • Treating-to-target in multiple sclerosis: Why, How...
Congress

Treating-to-target in multiple sclerosis: Why, How & When – expert panel insights at ECTRIMS 2021

ECTRIMS 2021

Novartis-sponsored satellite symposium, 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - 14th October, 2021 at 13:45-14:30 CET

  • Event type:
    Congress
  • Date
    14 Oct 2021 - 14 Oct 2021
  • Location
Register directly with ECTRIMS 2021

In this video trailer, meet our expert panel and hear their key insights on treating-to-target in multiple sclerosis (MS)


Symposium highlights:

  • Staying on ‘treatment target’ during COVID
  • Guidance on vaccination
  • Advances in MS pathology that bring us closer to personalised treatment
  • Use of high-efficacy treatments (HET) from ‘day one’
  • Young people with MS (18-19 years) rate their health status lower than those over 80 years in the general population

ECTRIMS Agenda.png

Register your interest in the satellite symposium to receive updates on ECTRIMS 2021 with Medthority

An error has occurred while getting captcha image

By clicking on the 'sign-up' button, you confirm you agree to receive further information about this symposium and related Medthority updates. To attend this event, you must register directly with ECTRIMS 2021 congress.

SOON on Medthority – Novartis-sponsored MS data from ECTRIMS 2021

Using HETs for MS from ‘day one’

Ofatumumab – explore the latest safety & efficacy data from the long-term Phase 3 ALITHIOS clinical trial, including data on serum immunoglobulin levels and microglial activity

Siponimod – learn about the first interim analysis from the clinical open-label, AMA-VACC study, assessing the immune response to SARS-CoV-2 mRNA vaccines in people with SPMS treated with siponimod

To explore Novartis-sponsored neurology medical educational content, please visit the One Neuroscience & Pain Learning Zone

Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non-Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. MLR ID: 159280